EU suspends Octagam
This article was originally published in Scrip
Europe's Committee for Medicinal Products for Human Use (CHMP) has recommended the suspension and recall of Octagam (human normal immunoglobulin), produced by Octapharma, in all European Union states. Earlier this month, German and Swedish regulators suspended their marketing authorisations for Octagam following an unexpectedly high number of reports of thromboembolic events, including stroke, myocardial infarction and pulmonary embolism in patients receiving the medicine.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.